Our mission is to identify novel therapeutics that target cellular pathways leading to enhanced mitochondrial function and improved human health. Mitobridge is a biotechnology company discovering and developing new small molecule modulators that boost mitochondrial functions. We are capitalizing on the latest biological findings that have revealed new insights into the complex mechanisms that regulate mitochondrial activities. The mitochondrion is a potential untapped target for drug discovery. Given the central role that they play in cellular functions, Mitobridge believes that pharmacological manipulation of this organelle will enable the establishment of novel medicines that address human diseases in new ways. Mitobridge is utilizing advanced technologies to develop a unique drug discovery platform for the identification and evaluation of compounds that effectively improve mitochondrial functions or correct mitochondrial dysfunctions. Our strategy is centered on the evolving scientific understanding of mitochondrial biology. Using a multi-faceted approach to discover small molecule compounds that address mitochondrial dysfunction, we are producing drug candidates that have the potential to treat a wide range of medical conditions, for example, metabolic, and musculoskeletal diseases, some of which may be genetic disorders. As a result, Mitobridge’s therapeutic candidates have the potential to address both rare diseases and conditions that affect large patient populations. Mitobridge has assembled an experienced management and scientific team with a proven track record for discovering ground-breaking drugs and building successful biotech companies. The Company was founded by world-renowned leaders in mitochondrial biology and metabolism. Mitobridge is funded by leading financial and corporate investors.
